Whole Exome Sequencing Market Current Scenario and Future Prospects
Market
Portrayal
A latest report
has been added to Market Research Future's offering in this COVID 19 pandemic
that states, the global Whole
Exome Sequencing Market 2020 might strike growth at a percent of 19.80
in the period of 2022-2030. With this, in this year also, the market would gain
revenue of USD 2,696.03 Million.
Top
Players
The top players
in the global whole exome sequencing market are BGI (China), Thermo Fisher
Scientific (US), F. Hoffmann-La Roche Ltd (Switzerland), Agilent Technologies,
Inc. (US), Ambry Genetics (US), Integragen SA (France), and Macrogen, Inc.
(South Korea).
Segment
Review
Global Whole
Exome Sequencing Market is studied over the segments of product, technology,
application, and end user.
·
The market, based on product
segment, has included sequencer, kits, and
services. Kits segment is further segmented into end repair, DNA fragmentation,
A-tailing, library preparation, size selection kits, and target enrichment.
Services segment is also further sub-segmented into Data Analysis
(Bioinformatics), Sequencing Services, and others.
·
The global whole exome
sequencing market, by technology segment, has included
ION semiconductor sequencing, Sequencing by Synthesis (SBS), and others.
·
The market by application
segment has included drug discovery, diagnostics, agriculture,
development, animal research, and others.
·
Based on end user segment, the market has included pharmaceutical & biotechnology companies,
hospitals and diagnostics centers, research centers and government institutes, and
others.
Whole Exome
Sequencing Drivers & Trends
The whole-exome
sequencing permits identifying the variations in the protein-coding sites of
any gene compared to sequencing a few genes mutually. The whole-exome
sequencing is preferred widely owing to its property to identify a mutation in
a single exon. Identifying mutation in at the original site makes whole-exome
sequencing a capable method and enables to identify possible disease-causing
mutation.
The global whole
exome sequencing market might expand at a rapid pace owing to factors such as
rapidly declining costs of sequencing, research institutes, strategic alliances
among major companies, adoption of WES technology by new consumers, and surge
in use of whole
exome sequencing technology for new applications.
Surge in
acceptance of next generation sequencing methods for treatment, prediction, and
monitoring of diverse chronic diseases such as cancer is possible to motivate
the market. In fact, the advancement in the field of genomics has also led to a
noteworthy reduction in the time and cost of genome sequencing.
Apart from this,
the associated cost of sequencing with different sequencing techniques and
strategies are of interest as they persuade the scope and scale of the genomic
research studies. Thus, it makes whole-exome sequencing much-preferred method
than whole-genome sequencing, which has become a well-defined factor for the
growth of the market.
On the contrary,
the factor of lack of skilled professionals and legal issues linked with the
technique might restrain the global whole exome sequencing market. In this case,
soaring demand for personalized medicine and development of new innovative
products by top players offer numerous opportunities for market expansion in the
coming years.
Regional
Framework
The Americas was the prevalent market for whole exome sequencing in
the year 2019. The growth of the Americas market happened owing to the towering
prevalence rate of cancer and other chronic disorders and rising healthcare
expenditure. Additionally, favorable initiatives by the government and other
organizations for the development and adoption of whole-exome sequencing
technologies are motivating the market for whole-exome sequencing. In the case
of point, in the year 2018, All of Us Research Program, a part of the National
Institutes of Health, awarded funds over USD 28.6 million to launch three
genome centers in the US. These centers intend to produce genome data for
researchers and the program’s precision medicine research platform, a national
resource to support studies on a variety of important health questions.
Europe is the second-prime market for whole exome sequencing.
Western Europe holds the leading market share. The European market might record
a muscular growth rate during the forecast period owing to intensifying cases
of cancer and rising programs for the adoption of genome sequencing. As per the
International Agency for Research on Cancer, in the year 2018, there were about
4,229,662 cases of cancer in Europe. These huge cases of cancer and rising
genome mapping programs might have a positive impact on the expansion of the
whole-exome sequencing market.
Asia-Pacific might represent the maximum market growth potential
over the forecast period owing to the increasing patient pool and rising
technological advancements. The fast growth of the Asia-Pacific region is owing
to the mounting per capita income along with government initiatives to enhance
the quality of healthcare. China, India, and Australia have a rewarding market
for Whole Exome Sequencing owing to the growing older population.
Browse Full Report: https://www.marketresearchfuture.com/reports/whole-exome-sequencing-market-8763
Related Report:
·
Dysmenorrhea
Treatment Market Research Report- Global Forecast to 2027
·
Syringe
and Needle Market Research Report - Global Forecast to 2027
·
Global
Medical Robotics Market Research Report- Forecast To 2027
Market Research
Future (MRFR) enable customers to unravel the complexity of various industries
through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw
Research Reports (3R), Continuous-Feed Research (CFR), and Market Research
& Consulting Services.
Contact us:
Market Research
Future (part of Wantstats Research and Media Private Limited),
99 Hudson
Street,5Th Floor, New York,
New York 10013
Comments
Post a Comment